Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 01, 2015 1:00 PM ET

Pharmaceuticals

Company Overview of Sprout Pharmaceuticals, Inc.

Company Overview

Sprout Pharmaceuticals, Inc. develops products for treatment of female sexual health. The company was founded in 2011 and is based in Raleigh, North Carolina.

4208 Six Forks Road

Raleigh, NC 27609

United States

Founded in 2011

Phone:

919-882-0850

Key Executives for Sprout Pharmaceuticals, Inc.

Co-Founder and Chief Executive Officer
Chief Financial Officer
Director and Secretary
Compensation as of Fiscal Year 2015.

Sprout Pharmaceuticals, Inc. Key Developments

Sprout Pharmaceuticals Receives U.S. Food and Drug Administration Approval of Addyi (Flibanserin 100 mg)

Sprout Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted approval of Addyi (flibanserin 100 mg) (pronounced add-ee), a once-daily, non-hormonal pill for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Addyi is the first and only FDA-approved treatment for this condition, the most common form of female sexual dysfunction, affecting up to 1 in 10 women in the United States. HSDD is defined as a persistent absence of sexual thoughts, fantasies, responsiveness and willingness to engage in sexual activity that causes personal or relationship distress and cannot be accounted for by another medical condition or substance. Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire. Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation or partner.

Sprout Pharmaceuticals, Inc. - Special Call

To discuss on U.S. Food and Drug Administration approval of Addyi™ (flibanserin 100 mg) (pronounced add-ee)

Sprout Pharmaceuticals Resubmits Flibanserin New Drug Application for The Treatment Of Hypoactive Sexual Desire Disorder In Premenopausal Women

Sprout Pharmaceuticals announced that it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for flibanserin, an investigational, once-daily, non-hormonal pill for Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women. If approved, flibanserin will be the first and only FDA-approved treatment for HSDD. Flibanserin was evaluated in three pivotal Phase 3, randomized, double-blind, placebo-controlled, parallel-group North American studies of premenopausal women with a mean age of 36 years. In all trials, flibanserin demonstrated a statistically significant difference compared to placebo on three key endpoints: an increase of sexual desire; a decrease in distress from the loss of sexual desire; and an increase in the frequency of satisfying sex.

Similar Private Companies By Industry

Company Name Region
Parke, Davis & Company LLC United States
Dauntless Pharmaceuticals, Inc. United States
Crown Laboratories, Inc. United States
Laniprin Life Sciences, Inc. United States
MBF Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
August 20, 2015
--
Private Placement
May 22, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Sprout Pharmaceuticals, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.